The Use of Recombinant FSH (Follitropin-β Solution) in Assisted Reproductive Techniques

陈新娜,卢光秀,严敬明,陈子江,肖红梅,陈贵安

DOI: https://doi.org/10.3969/j.issn.1003-6946.2006.05.014

2006-01-01

Abstract:Objective:To compare the efficacy and safety of recombinant-FSH (follitropin-β solution) and highly purified urinary FSH among Chinese women undergoing controlled ovarian hyperstimulation (COH) for IVF.Methods:Between March 2003 and November 2003,infertile female subjects were recruited at 4 IVF centers throughout China.A total of 227 women undergoing IVF with or without intracytoplasmic sperm injection (ICSI) were randomized into two groups (114 with follitropin-β,113 with highly purified urofollitropin).Each subject was treated with a long protocol of GnRH-agonist (Alarelin) for pituitary down-regulation.Results:No differences were found between two groups in number of oocytes retrieved,number of high quality embryos (6.61 versus 6.41),biochemical pregnancy rate per transfer and the number of follicles ≥17mm and ≥15mm in diameter on the day of hCG injection.However,compared to urinary FSH,the total dose of FSH was significantly lower with recombinant FSH (P<0.0001) in a significantly shorter treatment period (P<0.01).No significant differences between two groups were seen with respect to the incidence of OHSS and adverse events(P>0.05).Conclusions:Recombinant FSH (follitropin-β solution) is efficient and safe among Chinese women in COH for IVF with a lower overall total FSH dose and shorter treatment duration.